Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

@article{Furman1999DirectTO,
  title={Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.},
  author={Wayne L. Furman and Clinton F Stewart and Catherine A. Poquette and Charles B. Pratt and Victor M. Santana and William C. Zamboni and Laura C. Bowman and Margaret K Ma and Fredric A. Hoffer and William Meyer and Alberto S. Pappo and Andrew W. Walter and Peter James Houghton},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 6},
  pages={1815-24}
}
PURPOSE In a preclinical model of neuroblastoma, administration of irinotecan daily 5 days per week for 2 consecutive weeks ([qd x 5] x 2) resulted in greater antitumor activity than did a single 5-day course with the same total dose. We evaluated this protracted schedule in children. PATIENTS AND METHODS Twenty-three children with refractory solid tumors were enrolled onto a phase I study. Cohorts received irinotecan by 1-hour intravenous infusion at 20, 24, or 29 mg/m(2) (qd x 5) x 2 every… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 101 extracted citations

Similar Papers

Loading similar papers…